Vanguard Group Inc Aptevo Therapeutics Inc. Transaction History

Vanguard Group Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.17 - $0.38 $21,987 - $49,148	-129,339 Reduced 58.51%	91,725 $16,000
Q3 2023 Nov 14, 2023	SELL	$0.31 - $1.78 $2,405 - $13,812	-7,760 Reduced 3.39%	221,064 $72,000
Q2 2023 Aug 14, 2023	SELL	$1.34 - $2.08 $718 - $1,114	-536 Reduced 0.23%	228,824 $334,000
Q1 2023 May 15, 2023	SELL	$1.74 - $2.54 $16,738 - $24,434	-9,620 Reduced 4.03%	229,360 $467,000
Q4 2022 Feb 10, 2023	BUY	$2.0 - $138.16 $272 - $18,789	136 Added 0.06%	238,980 $554,000
Q2 2022 Aug 12, 2022	SELL	$3.26 - $6.3 $6,438 - $12,442	-1,975 Reduced 0.82%	238,844 $855,000
Q1 2022 May 13, 2022	BUY	$4.48 - $8.42 $73,189 - $137,557	16,337 Added 7.28%	240,819 $1.41 Million
Q4 2021 Feb 14, 2022	BUY	$6.48 - $17.49 $578,080 - $1.56 Million	89,210 Added 65.95%	224,482 $1.77 Million
Q3 2021 Nov 12, 2021	BUY	$15.01 - $22.16 $7,685 - $11,345	512 Added 0.38%	135,272 $2.09 Million
Q2 2021 Aug 13, 2021	BUY	$21.85 - $30.0 $2.94 Million - $4.04 Million	134,760 New	134,760 $3.02 Million

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.